Trial Profile
CXCR2 inhibition: a novel approach to treating coronary heart disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2023
Price :
$35
*
At a glance
- Drugs AZD 5069 (Primary)
- Indications Coronary disorders
- Focus Therapeutic Use
- 17 Mar 2023 Status changed from completed to discontinued due to Participant recruitment issue.
- 28 Feb 2022 Status changed from active, no longer recruiting to completed.
- 07 Aug 2020 Planned End Date changed from 31 Dec 2017 to 28 Feb 2022.